The therapeutic scenario for multiple myeloma (MM) has changed drastically in recent years
with the introduction of new molecules, which lead to a more precise medicine, improving …

Multiple myeloma (MM) is characterized by multiple relapse and, despite the introduction of
novel therapies, the disease becomes ultimately drug-resistant. The tumor …

Immune-mediated neuropathy (IMN) is a group of heterogenous neuropathies caused by
intricate autoimmune responses. For now, known mechanisms of different IMN subtypes …

Background Daratumumab, an anti-CD38 monoclonal antibody, is used for treatment of
multiple myeloma (MM) and light chain amyloidosis at an intravenous dosage of 16 mg/kg or …

Background Viral reactivations are frequent in hematologial patients due to their cancer‐
related and drug‐induced immunosuppressive status. Daratumumab, an anti‐CD38 …

Isatuximab, a novel anti‐CD38 monoclonal antibody, is approved in combination with
carfilzomib and dexamethasone (Isa‐Kd) in relapsed/refractory multiple myeloma (RRMM) …

The microenvironment plays an essential role in multiple myeloma (MM) development,
progression, cell proliferation, survival, immunological escape, and drug resistance …

In the realm of malignant tumor treatment, particularly regarding hematologic malignancies,
chimeric antigen receptor T‐cell (CAR‐T) immunotherapy has witnessed remarkable …

Light chain deposition disease (LCDD) is a rare, clonal plasma cell proliferative condition.
The deposition of nonamyloid monoclonal immunoglobulin light chains predominantly …

Teclistamab is a B‑cell maturation antigen (BCMA)-directed bispecific antibody approved for
the treatment of patients with triple-class exposed relapsed/refractory multiple myeloma. In …